Literature DB >> 18347458

Multiple intracranial meningiomas causing papilledema and visual loss in a patient with nevoid Basal cell carcinoma syndrome.

Jonathan T Pribila1, Shawn M Ronan, Jonathan D Trobe.   

Abstract

A 27-year-old man with nevoid basal cell carcinoma syndrome (NBCCS, Gorlin syndrome) who had undergone craniospinal irradiation for a childhood brain stem medulloblastoma complained of progressive binocular visual loss. Ophthalmologic examination disclosed subnormal visual acuity and visual fields in both eyes attributed to chronic papilledema. Brain MRI demonstrated mass effect from multiple large meningiomas. After embolization and surgical resection of the largest meningioma, papilledema disappeared and visual dysfunction resolved partially. This is the sixth reported patient with NBCCS, medulloblastoma, and craniospinal radiation who has developed intracranial meningioma, further documenting the fact that such patients have a relatively high likelihood of developing meningiomas, especially multiple meningiomas. Because patients with NBCCS are often mentally impaired and because papilledema can progress silently before causing irreversible visual loss, periodic ophthalmologic examination is advisable after craniospinal radiation.

Entities:  

Mesh:

Year:  2008        PMID: 18347458     DOI: 10.1097/WNO.0b013e318167540e

Source DB:  PubMed          Journal:  J Neuroophthalmol        ISSN: 1070-8022            Impact factor:   3.042


  2 in total

1.  Two cases of nevoid basal cell carcinoma syndrome associated with meningioma caused by a PTCH1 or SUFU germline mutation.

Authors:  Chihiro Kijima; Toshiyuki Miyashita; Maiko Suzuki; Hidehiro Oka; Kiyotaka Fujii
Journal:  Fam Cancer       Date:  2012-12       Impact factor: 2.375

Review 2.  Review of Ocular Manifestations of Nevoid Basal Cell Carcinoma Syndrome: What an Ophthalmologist Needs to Know.

Authors:  Judy J Chen; Juliana Sartori; Vinay K Aakalu; Pete Setabutr
Journal:  Middle East Afr J Ophthalmol       Date:  2015 Oct-Dec
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.